G CSF Antibody

Granulocyte Colony Stimulating Factor (G-CSF) is a glycoprotein that plays a crucial role in hematopoiesis, the process of forming blood cellular components. It specifically stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. G-CSF is widely used in clinical settings to treat neutropenia, a condition characterized by an abnormally low count of neutrophils, which are a type of white blood cell essential for fighting infections .

G-CSF binds to its receptor (G-CSFR) on the surface of hematopoietic progenitor cells, leading to their proliferation and differentiation into neutrophils . This binding activates several intracellular signaling pathways, including the JAK/STAT, PI3K/AKT, and Ras/MAPK pathways, which are involved in cell survival, proliferation, and differentiation .

G-CSF is FDA-approved for several clinical applications, including:

• Treatment of Neutropenia: G-CSF is used to treat neutropenia in patients undergoing chemotherapy, bone marrow transplantation, or those with chronic neutropenia .
• Stem Cell Mobilization: It is used to mobilize hematopoietic stem cells from the bone marrow into the peripheral blood for collection and subsequent transplantation .

Mouse anti-human G-CSF antibodies are monoclonal antibodies produced by immunizing mice with human G-CSF. These antibodies are used in research and diagnostic applications to detect and quantify human G-CSF levels in various biological samples .

G-CSF has shown promise in various research and therapeutic areas beyond hematopoiesis:

• Neuroprotection: G-CSF displays neuroprotective properties and has been studied for its potential in treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and stroke .
• Anti-Apoptotic and Immunomodulatory Effects: G-CSF has anti-apoptotic and immunomodulatory properties, making it a candidate for treating inflammatory and autoimmune diseases .